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AP-4 vesicles contribute to spatial control of
autophagy via RUSC-dependent peripheral
delivery of ATG9A
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Adaptor protein 4 (AP-4) is an ancient membrane trafficking complex, whose function has
largely remained elusive. In humans, AP-4 deficiency causes a severe neurological disorder of
unknown aetiology. We apply unbiased proteomic methods, including ‘Dynamic Organellar
Maps’, to find proteins whose subcellular localisation depends on AP-4. We identify three
transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3, and two AP-4 accessory
proteins, RUSC1 and RUSC2. We demonstrate that AP-4 deficiency causes missorting of
ATG9A in diverse cell types, including patient-derived cells, as well as dysregulation of
autophagy. RUSC2 facilitates the transport of AP-4-derived, ATG9A-positive vesicles from
the trans-Golgi network to the cell periphery. These vesicles cluster in close association with
autophagosomes, suggesting they are the “ATG9A reservoir” required for autophagosome
biogenesis. Our study uncovers ATG9A trafficking as a ubiquitous function of the AP-4
pathway. Furthermore, it provides a potential molecular pathomechanism of AP-4 deficiency,
through dysregulated spatial control of autophagy.
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Eukaryotic cells use a highly regulated system of vesicular andtubular transport intermediates to exchange moleculesbetween organelles. Adaptor protein complex 4 (AP-4) is
one of five related heterotetrameric AP complexes, which selec-
tively incorporate transmembrane cargo proteins into nascent
vesicles, and recruit machinery for vesicle budding and trans-
port1. AP-4 consists of four subunits (β4, ε, μ4 and σ4) forming
an obligate complex2–4 (Fig. 1a). Loss-of-function mutations in
any of the genes (AP4B1, AP4E1, AP4M1 and AP4S1) cause a
severe recessive neurological disorder with early-onset progressive
spastic paraplegia and intellectual disability5–7. AP-4-deficient
patients have brain abnormalities including thinning of the cor-
pus callosum6,8–10, indicating an important role for AP-4 in
neuronal development and homoeostasis. Axons of Purkinje
and hippocampal neurons from Ap4b1 knockout mice contain
aberrantly accumulating autophagosomes that are immuno-
positive for AMPA receptors11. However, the link between AP-
4 deficiency and dysregulation of autophagy remains unclear.
While the clathrin adaptors AP-1 and AP-2 are well char-
acterised, the function of AP-4, which does not associate with
clathrin, has remained elusive. At steady state AP-4 localises to
the trans-Golgi network (TGN)2,3 and so is presumed to mediate
cargo sorting at the TGN. The destination of the AP-4 trafficking
pathway remains controversial, with conflicting reports suggest-
ing transport to early endosomes12,13, to late endosomes/lyso-
somes14 and, in polarised epithelial cells, to the basolateral
membrane15. Likewise, AP-4 has been suggested to influence the
sorting of various cargoes, including amyloid precursor pro-
tein12,13,16, low-density lipoprotein receptor11,15, AMPA recep-
tors11, and δ2 glutamate receptors11,17. However, several of these
studies relied on exogenously expressed proteins, while the
potential endogenous cargoes (e.g., δ2 glutamate receptor) have
cell-type-limited expression, unlike AP-4, which is ubiquitously
expressed2,3. There is currently no consensus as to which proteins
are genuine cargoes of the AP-4 pathway, and hence no con-
sensus as to its function. Similarly, AP-4 vesicle machinery is
largely uncharacterised. The only identified AP-4 accessory
protein is a cytosolic protein of unknown function called
TEPSIN18.
Due to the very low abundance of AP-4 (ca. 40-fold lower than
AP-1 or AP-2 in HeLa cells19), its functional characterisation has
proved challenging. Nonetheless, given its ubiquitous expression
in human tissues, AP-4 is likely to play a ubiquitous and
important role in protein sorting, whose identification will be
paramount to understanding AP-4 deficiency. Here, we combine
orthogonal, unbiased and sensitive proteomic approaches to
define the composition of AP-4 vesicles. From the intersection of
our analyses we identify physiological cargo proteins of the AP-4
pathway, and AP-4 accessory proteins. We demonstrate that AP-
4 is required for the correct sorting of three transmembrane cargo
proteins, including ATG9A, a protein with a key role in autop-
hagosome biogenesis. Thus, our data suggest a potential
mechanistic explanation for the pathology caused by AP-4 defi-
ciency, through dysregulation of autophagy caused by mis-
trafficking of ATG9A.
Results
ATG9A, SERINC1 and SERINC3 are AP-4 cargo proteins. In
AP-4-deficient cells, transmembrane cargo proteins that are
usually transported in AP-4 vesicles, and cytosolic accessory
proteins that are normally recruited by AP-4, are likely to be
mislocalised. As an unbiased screen for such proteins, we used the
‘Dynamic Organellar Maps’ approach recently developed in our
laboratory19,20. This mass spectrometry (MS)-based method
provides protein subcellular localisation information at the
proteome level (Fig. 1b). A comparison of maps made from cells
with genetic differences allows the detection of proteins with
altered subcellular localisation.
We prepared maps from wild-type, AP4B1 knockout and
AP4E1 knockout HeLa cells (Fig. 1c and Supplementary
Fig. 1a, b), in biological duplicate (Fig. 1d and Supplementary
Data 1). For every protein, we calculated the magnitude of
localisation shifts between the wild-type and each knockout,
and the reproducibility of the shift direction (Fig. 1e). Three
proteins underwent significant and reproducible shifts in both
knockout cell lines: SERINC1 and SERINC3 (Serine incor-
porator 1 and 3), multi-pass membrane proteins of unknown
function, and ATG9A (Autophagy-related protein 9A; Fig. 1f).
ATG9A is the only transmembrane core autophagy protein
and is thought to play a key (though poorly defined) role in
the initiation of autophagosome formation21. The altered
subcellular distribution of these proteins in AP-4-deficient
cells identified them as candidate cargo proteins for the AP-4
pathway.
To begin to interpret the nature of the detected shifts, we used
subcellular localisation information inferred from the maps. In
both wild-type and AP-4 knockout cells, ATG9A and SERINCs
mapped to the endosomal cluster (Fig. 1g–i). However, this
cluster comprises different types of endosomes, as well as the
TGN19. Scrutiny of the map visualisations (Fig. 1g–i) and marker
protein neighbourhood analysis (Supplementary Data 2) sug-
gested that in the knockouts both SERINCs shifted intra-
endosomally, while ATG9A localisation shifted from endosomes
towards the TGN.
RUSC1 and RUSC2 are cytosolic AP-4 accessory proteins.
Cytosolic proteins that only transiently associate with membranes
may be missed by the Dynamic Organellar Maps approach,
especially if they have low expression levels. We hence applied
another proteomic approach developed in our lab, comparative
vesicle profiling18, to identify proteins lost from a vesicle-enriched
fraction in the absence of AP-4 (Fig. 2a). This is particularly
suited for identifying vesicle coat proteins. Cargo proteins are
sometimes less strongly affected, as they may exist in several
vesicle populations18.
We used four different methods to ablate AP-4 function: (i)
knockdown; (ii) knocksideways (whereby a protein is rerouted to
mitochondria, acutely depleting its cytosolic pool22); (iii) knock-
out of AP4B1; (iv) knockout of AP4E1. Binary comparisons of
AP-4-depleted and control vesicle fractions were performed by
MS (Supplementary Fig. 2a and Supplementary Data 3) and
principal component analysis was used to combine the informa-
tion from all datasets (Fig. 2b). Proteins that were reproducibly
lost from vesicle fractions from AP-4-depleted cells included the
AP-4 subunits and TEPSIN, while SERINC1 and SERINC3 were
the most depleted membrane proteins. ATG9A was affected to a
lesser extent. Two related cytosolic proteins, RUSC1 and
RUSC2 (RUN and SH3 domain-containing protein 1 and 2;
Fig. 2c), were also reproducibly lost (Fig. 2b). They were not
included in the maps since they are barely detectable in
subcellular membrane fractions. However, both proteins are
highly enriched in the vesicle fraction, suggesting they are vesicle-
associated proteins.
To investigate the RUSC-AP-4 relationship, we analysed total
membrane fractions and whole cell lysates from control and AP-4
knockout cells by deep sequencing MS. RUSC2 (which has a
lower whole cell copy number than RUSC119) was not
consistently detected, but RUSC1 was dramatically lost from
the total membrane fraction (>4-fold; Fig. 2d) and the whole cell
lysate (>3-fold; Supplementary Fig. 1c) in knockout cells
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Fig. 1 Dynamic Organellar Maps detect mislocalisation of ATG9A, SERINC1 and SERINC3 in AP-4 knockout (KO) HeLa cells. a Diagram of the AP-4
complex. b Workflow for Dynamic Organellar Map generation. Cell lysates are subjected to a series of differential centrifugation steps, to achieve partial
separation of organelles. Proteins in each fraction are quantified by mass spectrometry (MS), to obtain abundance distribution profiles. Proteins associated
with the same organelle have similar profiles. Clustering can be visualised by principal component analysis (PCA) and compartment assignments are made
through support vector machine (SVM)-based classification. c Western blot of whole cell lysates from wild-type, AP4B1 KO and AP4E1 KO HeLa cells; α-
Tubulin, loading control. Representative of two independent experiments. d Experimental design for AP-4 Dynamic Organellar Mapping. Maps were made
from wild type, AP4B1 KO and AP4E1 KO cell lines, each in duplicate. Profiles from each KO map were subtracted from the cognate control profiles, to
obtain two AP4E1 Δmaps, and two AP4B1 Δmaps. Proteins that did not shift had similar profiles in wild-type and AP-4 KO maps, and hence Δ profiles close
to zero. To identify significantly translocating proteins, the magnitude of shift (M) and the reproducibility of shift direction (R) were scored for each protein
and each Δmap. e MR plot analysis of AP-4 Dynamic Organellar Mapping. 3926 proteins were profiled across all maps. Three proteins whose subcellular
localisation was significantly and reproducibly shifted across the AP-4 KO lines were identified with very high confidence (FDR < 1%). The analysis only
covered proteins profiled across all maps; since AP-4 itself was not present in the KO maps, it was not included. See also Supplementary Data 1. f Topology
of the proteins identified by AP-4 Dynamic Organellar Mapping. g–i Visualisation of organellar maps by PCA. Each scatter point represents a protein;
proximity indicates similar fractionation profiles. Known organellar marker proteins are shown in colour, and form clusters. Each plot combines the data
from two independent map replicates. g wild-type; h AP4B1 KO; i AP4E1 KO. The three proteins that undergo significant shifts in AP-4 KOs are annotated
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(Supplementary Data 4). This suggests that without AP-4, RUSC
proteins are no longer recruited to the membrane, leading to their
destabilisation. Mutations in RUSC2 have been reported in
patients with phenotypes reminiscent of AP-4 deficiency23.
Collectively, these data suggest that RUSC1 and RUSC2 are
AP-4 accessory proteins.
AP-4 interacts with ATG9A, SERINCs and RUSC2. AP
complex-cargo interactions are transient and so have largely
proved refractory to standard co-immunoprecipitation approa-
ches. As an alternative we applied BioID, which uses a pro-
miscuous biotin ligase, BirA*, to biotinylate proteins proximal to
a protein of interest24. We stably expressed AP4E1-BirA* in HeLa
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cells and quantified biotinylated proteins by MS relative to con-
trols (Fig. 2e and Supplementary Data 5). AP4E1-BirA* sig-
nificantly biotinylated the other three AP-4 subunits and TEPSIN.
ATG9A was the only significantly enriched transmembrane
protein, consistent with it being an AP-4 cargo protein. SERINC1
and SERINC3 were not identified, likely due to low availability of
lysine residues (the target of activated biotin) in their small
cytosolic loops24,25. In addition, RUSC2 was significantly enri-
ched, supporting its candidacy as an AP-4 accessory protein.
Consistent results were obtained with AP4M1-BirA* (Supple-
mentary Fig. 2b–d).
We next performed co-immunoprecipitation of the AP-4
complex via overexpressed TEPSIN-GFP, under sensitive low-
detergent conditions (Fig. 2f and Supplementary Data 4).
ATG9A, SERINC1 and SERINC3 were co-precipitated, confirm-
ing that they are cargo proteins of the AP-4 pathway. As
expected, these interactions were not observable with a conven-
tional immunoprecipitation protocol (Supplementary Fig. 2e).
Most AP complex accessory proteins interact with one or both
C-terminal “ear” domains of the large subunits, including
TEPSIN, which binds to the AP-4 β and ε appendage
domains26,27. As RUSC2 was identified by BioID, we tested
whether GFP-RUSC2 would interact with either of the appendage
domains in a GST pull-down experiment. GFP-RUSC2, but not
GFP alone, was pulled down with both appendage domains,
notably at higher levels with the ε ear (Fig. 2g), confirming that
RUSC2 is a bona fide AP-4 ear interaction partner.
In sum, using orthogonal proteomic approaches, we have
identified three AP-4 cargo proteins, ATG9A, SERINC1 and
SERINC3, and two AP-4 accessory proteins, RUSC1 and RUSC2.
These are all low abundance proteins, expressed at comparable
levels to AP-4 in HeLa cells19 (Fig. 2h) and primary mouse
neurons20.
ATG9A accumulates at the TGN of AP-4 deficient cells. To
further characterise the ATG9A missorting phenotype we used
immunofluorescence microscopy. In wild-type cells, ATG9A was
detected as fine puncta with increased density in the juxtanuclear
region (Fig. 3a), consistent with previous data28. In contrast, there
was a striking accumulation of ATG9A in the TGN region in both
AP-4 knockout lines (Fig. 3a and Supplementary Fig. 3).
Importantly, the mislocalisation of ATG9A in the AP4B1
knockout was completely rescued by stable expression of the
AP4B1 subunit (Fig. 3a). This was confirmed by quantitative
automated imaging (Fig. 3b). To determine whether ATG9A is
similarly affected by loss of AP-4 in a cell line more relevant to
the neuronal phenotypes of AP-4 deficiency, we used CRISPR/
Cas9-mediated gene editing to deplete AP4B1 or AP4E1 in mixed
populations of SH-SY5Y neuroblastoma cells (Fig. 3c). As before,
loss of AP-4 caused a striking accumulation of ATG9A at the
TGN (Fig. 3d).
To test if ATG9A missorting also occurs in individuals with
AP-4 deficiency, we analysed fibroblasts from patients with
homozygous mutations in one of the AP-4 genes5,6,29,30 by
immunofluorescence microscopy (Fig. 4a). Mutations in any of
the four subunits caused a striking accumulation of ATG9A at the
TGN. In addition, fibroblasts from an individual with a
heterozygous loss-of-function mutation in AP4E1 (the phenoty-
pically normal mother of the homozygous AP4E1 patient)
displayed normal ATG9A localisation, so mislocalisation of
ATG9A is a cellular phenotype that correlates with disease in
AP-4 deficiency.
The microscopy indicated that there was also an increase in the
overall ATG9A signal in the patient cells, both within and outside
the TGN region. Western blotting confirmed a large increase in
the amount of ATG9A in whole cell lysates from all four patient
cell lines and an intermediate level in the unaffected AP4E1
heterozygote (Fig. 4b). These data suggest that in some cases AP-
4-deficient cells may compensate for the missorting of ATG9A by
increasing its expression, further supporting the importance of
AP-4 in the regulation of ATG9A trafficking. However, there was
no increase in ATG9A in whole cell lysates from the AP-4
knockout HeLa cell lines (Supplementary Fig. 1c), so the
accumulation of ATG9A at the TGN does not simply reflect an
increase in expression, but rather a kinetic delay in TGN export in
the absence of AP-4.
ATG9A and SERINCs colocalise in AP-4 dependent vesicles.
Since there are no commercial antibodies that allow detection of
endogenous SERINC1 or SERINC3, we used CRISPR to knock in
fluorescent Clover tags at the endogenous loci in HeLa cells
(Supplementary Fig. 4a). Confocal microscopy with Airyscan
enhanced resolution revealed the tagged SERINCs to localise to
the perinuclear region and fine puncta throughout the cell
(Fig. 5a, c). Strikingly, the peripheral SERINC-positive puncta
showed considerable overlap with ATG9A, and AP-4 knockdown
resulted in loss of these puncta, suggesting they were AP-4-
derived vesicles (Fig. 5a–d and Supplementary Fig. 4b). Fur-
thermore, in the AP-4-depleted cells the SERINCs accumulated in
the perinuclear area but, unlike ATG9A, they displayed little
colocalisation with TGN46 (Supplementary Fig. 4c, d). Although
ATG9A and SERINCs are both cargoes of the AP-4 pathway, they
Fig. 2 Multiple orthogonal proteomic approaches confirm ATG9A, SERINC1 and SERINC3 as AP-4 cargo proteins and identify RUSC1 and RUSC2 as AP-4
accessory proteins. aWorkflow for proteomic vesicle profiling. Vesicle-enriched fractions were prepared in pairs from metabolically (SILAC heavy or light)
labelled control and AP-4-depleted cells and compared by quantitative MS. 2848 proteins were quantified across all experiments. b PCA combining the
SILAC ratios from nine comparative AP-4-depleted vesicle fraction experiments. Proteins consistently lost from the vesicle fraction of AP-4-depleted cells
are in the top-right section. c Domain organisation of RUSC1 and RUSC2. There are additional RUSC1 isoforms, but our MS data identified the isoform
shown as predominant in our samples. d Comparison of protein abundance in total membrane fractions prepared from AP-4 KO (AP4B1 and AP4E1, each in
triplicate, n= 6) and wild-type HeLa cells (in triplicate, n= 3), analysed by label-free quantitative MS. >6600 proteins were quantified; RUSC1 was the only
protein significantly depleted from the membrane fraction of AP-4 KO cells (RUSC2 and AP-4 subunits were not consistently detected). Data were
analysed with a two-tailed t-test: volcano lines indicate the significance threshold (FDR= 5%). e Comparison of protein abundance in affinity purifications
of biotinylated proteins from HeLa cells stably expressing AP4E1-BirA*, and control cell lines (HeLa, HeLa BirA* and HeLa GFP-BirA*), analysed by label-
free quantitative MS and volcano analysis as in d. The experiment was performed in triplicate and the control dataset was compressed to the three highest
LFQ intensities per protein. >3100 proteins were quantified; FDR= 5%. f High-sensitivity low-detergent immunoprecipitations from HeLa cells stably
expressing the AP-4 associated protein TEPSIN-GFP. The scatter plot shows two replicate SILAC comparisons of TEPSIN-GFP immunoprecipitations versus
mock immunoprecipitations (from parental HeLa). TEPSIN-GFP associated proteins have high ratios. g Western blots of GST pulldowns using GST-ε
(883–1137), GST-β4 (612–739) or GST, from cytosol from HeLa cells stably expressing GFP-RUSC2, or GFP alone as a control. Input cytosol is also shown.
Representative of two independent experiments. h Estimated copy numbers of AP4B1, AP4E1, AP4M1, TEPSIN, RUSC1, RUSC2, ATG9A, SERINC1 and
SERINC3, in HeLa cells, from previously published data19 (means +/- SD; n= 6)
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also independently (and perhaps differentially) utilise other
trafficking machinery, as evidenced by their partially non-
overlapping subcellular distributions in wild-type cells. This
may account for different types of perinuclear retention observed
in the absence of AP-4.
RUSC2 drives peripheral accumulation of ATG9A vesicles. We
next created HeLa cell lines that stably overexpress GFP-tagged
RUSC2 and found it to localise to fine puncta throughout the cell,
with a concentration in clusters at the periphery (Fig. 6a and
Supplementary Fig. 5a). Overexpression of RUSC2 resulted in a
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dramatic relocation of ATG9A and SERINCs to the cell periph-
ery, where they colocalised with the GFP-tagged RUSC2 (Fig. 6a,
b and Supplementary Fig. 5a, b). This effect was specific for AP-4
cargo proteins; other membrane proteins and organellar markers
did not respond to overexpression of RUSC2 (Supplementary
Fig. 5c).
The localisation of AP-4 itself was not affected by RUSC2
overexpression (Supplementary Fig. 6a), but we hypothesised that
the peripheral structures in RUSC2-overexpressing cells might be
AP-4-derived vesicles. Consistent with this, GFP-RUSC2
expressed in AP-4 knockout or knockdown cells neither
accumulated at the cell periphery, nor colocalised with ATG9A
(Fig. 7a and Supplementary Fig. 6b, c). Importantly, both the
peripheral distribution of GFP-RUSC2 and its colocalisation with
ATG9A were restored in the AP4B1 knockout by transient
expression of the missing AP-4 subunit (Fig. 7a). This
demonstrates that the peripheral RUSC2/ATG9A/SERINC-
positive structures are AP-4-dependent compartments. The
absence of AP-4 from the accumulating structures suggests that
it is released soon after vesicle budding, as is typical of most
known vesicle coats1.
Given the colocalisation between RUSC2 and ATG9A, we
tested whether ATG9A and GFP-RUSC2 interact physically.
ATG9A co-precipitated with GFP-RUSC2 from wild-type but not
AP4B1 knockout cells (Fig. 7b). This demonstrates that the
interaction between RUSC2 and ATG9A (which could be
indirect) requires AP-4, suggesting that the three proteins come
together transiently during the formation of AP-4 vesicles.
Ultrastructural analysis by correlative light and electron
microscopy (CLEM) revealed that the peripheral clusters of
GFP-RUSC2-positive puncta corresponded to an accumulation
of uncoated vesicular and tubular structures (Fig. 7c). Their per-
ipheral localisation suggested targeting to the plus-ends
of microtubules, and RUSCs have been implicated in
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Fig. 4 ATG9A mislocalisation is a ubiquitous phenotype in cells from AP-4-deficient patients. a Widefield imaging of fibroblasts from a healthy control
individual, patients with homozygous mutations in one of the four AP-4 genes, and an individual with a heterozygous (Het) mutation in AP4E1
(phenotypically normal mother of the AP4E1* patient), labelled with anti-ATG9A and anti-TGN46. In the merged image, DAPI labelling of the nucleus is
also shown (blue). Scale bar: 20 µm. b Western blots of whole cell lysates from the cells shown in a; Clathrin heavy chain, loading control. Representative
of two independent experiments
Fig. 3 ATG9A accumulates at the trans-Golgi network (TGN) in AP-4 knockout HeLa and SH-SY5Y cells. a Widefield imaging of immunofluorescence
double labelling of ATG9A and TGN46 in wild-type (WT), AP4B1 KO, and AP4B1 KO HeLa cells stably expressing AP4B1 (rescue). Scale bar: 20 μm.
b Quantification of the ratio of ATG9A labelling intensity between the TGN and the rest of the cell using an automated microscope. Ratios were normalised
to the mean wild-type ratio. The experiment was performed in biological triplicate (mean indicated, n= 3), and >1400 cells were scored per cell line in each
replicate. Data were subjected to one-way ANOVA with Dunnett’s Multiple Comparison Test for significant differences from the wild-type: ***p≤ 0.001;
ns p > 0.05. c SH-SY5Y (neuroblastoma) cells stably expressing Cas9 were transduced with sgRNAs to AP4B1 or AP4E1. Mixed populations were selected
for sgRNA expression and parental Cas9-expressing SH-SY5Y cells were used as a control. Western blot of whole cell lysates; α-Tubulin, loading control.
Representative of two independent experiments. d Widefield imaging of immunofluorescence double labelling of ATG9A and TGN46 in control, AP4B1
depleted and AP4E1 depleted SH-SY5Y cells. Scale bar: 20 μm
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microtubule-based transport31. Treatment with nocodazole pre-
vented the peripheral localisation of GFP-RUSC2 but, unlike in
AP-4-deficient cells, GFP-RUSC2 still co-localised with ATG9A
(Fig. 7d). These data suggest that the distribution of AP-4 vesicles
requires microtubule-based transport, whereas their formation
does not.
Loss of AP-4 or RUSCs causes dysregulation of autophagy.
Ap4b1 knockout mice show aberrant accumulation of autopha-
gosomes in neuronal axons, and increased levels of the autop-
hagic marker protein LC3B11. We investigated if there were
similar effects on autophagy in our AP-4 knockout HeLa cells.
Wild-type and AP4E1 knockout cells were grown in complete or
starvation medium (to induce autophagy), with or without bafi-
lomycin A1 (which blocks autophagosome degradation). The
level of LC3B was then assessed by Western blotting (Fig. 8a). In
untreated cells, there were increased levels of both unlipidated
LC3B-I and lipidated LC3B-II in the AP4E1 knockout. In addi-
tion, the ratio of LC3B-II to LC3B-I was decreased. Under star-
vation conditions (when LC3B-I is mostly converted into LC3B-
II), there was also increased LC3B-II in the AP4E1 knockout,
which increased further in the presence of bafilomycin A1. This
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Fig. 5 ATG9A and SERINC colocalisation in peripheral puncta is dependent on AP-4. CRISPR/Cas9 gene editing was used to introduce a C-terminal Clover
(modified GFP) tag to endogenous SERINC1 or SERINC3 in HeLa cells. Cells were transfected with siRNA to knock down AP-4, or were mock transfected
(without siRNA) as a control. a Confocal microscopy with Airyscanning was used to image SERINC1-Clover (via anti-GFP) and anti-ATG9A. Representative
images show a confocal slice of the whole cell, and a peripheral 10 × 10 μm square imaged with Airyscanning in Superresolution mode, used for the
quantification of colocalisation between SERINC1-Clover and ATG9A. Scale bar: 10 μm. b Quantification of colocalisation between SERINC1-Clover and
ATG9A in peripheral regions of mock treated and AP-4 knockdown (KD) cells, using Thresholded Pearson’s Correlation Coefficient. 20 cells were
quantified per condition. Data show mean (n= 20), and results of a two-tailed Mann–Whitney U-test: ***p≤ 0.001. c Confocal microscopy with
Airyscanning was used to image SERINC3-Clover (via anti-GFP) and anti-ATG9A, as in a. d Quantification of colocalisation between SERINC3-Clover and
ATG9A in peripheral regions of mock treated and AP-4 knockdown cells, using Thresholded Pearson’s correlation coefficient. 19 cells were quantified per
condition. Data show mean (n= 19), and results of a two-tailed Mann–Whitney U-test: ***p≤ 0.001
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suggests that the elevated level of LC3B-II was not due to a block
in degradation. The same trends were seen when comparing
AP4B1 knockout cells with the AP4B1 rescued cell line (Fig. 8b).
Quantitative MS confirmed the increased level of total LC3B in
whole cell lysates of untreated AP-4 knockout cells (median 1.5-
fold increase; Supplementary Fig. 1c and Supplementary Data 4).
Elevated LC3B-II may reflect an increase in autophagosome
size32. To test this, we visualised LC3B-positive structures by
immunofluorescence microscopy in wild-type, AP4B1 knockout,
and AP4B1 rescued cells, following two hours starvation (Fig. 8c).
Quantification through automated imaging showed an increase in
the size of LC3B puncta in the knockout cells (Fig. 8d), but no
significant change in the number of puncta (Supplementary
Fig. 7a). Larger LC3B puncta were also observed in AP4E1
knockout cells (Supplementary Fig. 7b). Collectively, these data
suggest that lack of AP-4 in HeLa cells causes dysregulation of
autophagy.
Given the aberrant autophagy caused by loss of AP-4, we tested
whether siRNA-mediated knockdown of either RUSC1, RUSC2,
or both together, might also affect autophagy. Transcript levels
from both genes were robustly reduced by around 70% (Fig. 8e, f).
Knockdown of RUSC1 alone had no effect on the level of LC3B in
HeLa cells grown in complete or starvation medium (Fig. 8g). In
contrast, knockdown of RUSC2 resulted in clear alterations to the
level of LC3B in both basal and starvation conditions, similar to
the effect of loss of AP-4 (Fig. 8a, b, g). Loss of both RUSC
proteins had an additive effect, resulting in further elevated
LC3B-I and –II levels (Fig. 8g). These data establish RUSCs as
important AP-4 accessory proteins and suggest at least partial
functional redundancy between RUSC1 and RUSC2.
ATG9A/RUSC2-positive vesicles associate with autophago-
somes. In contrast to the effect of RUSC2 depletion on autop-
hagy, LC3B levels were unaffected by overexpression of RUSC2,
in both basal and starvation conditions (Supplementary Fig. 8a,
b). Immunofluorescence microscopy showed similar LC3B-
labelling in wild-type and RUSC2-overexpressing HeLa cells
grown in full medium (Supplementary Fig. 8c). Interestingly,
starvation induced a change in the localisation of RUSC2-positive
puncta, away from the periphery of the cell (Fig. 9a and Sup-
plementary Fig. 9a). These puncta were still positive for ATG9A
and were often found in very close proximity to LC3B-positive
puncta, which appeared larger in the RUSC2-overexpressing cells.
Airyscan confocal microscopy revealed the RUSC2-positive and
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Fig. 6 ATG9A-positive and SERINC-positive puncta accumulate at the cell periphery in RUSC2-overexpressing cells. a Widefield imaging of HeLa cells
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LC3B-positive puncta to be separate structures, which were often
closely associated (Fig. 9b). The localisation of GFP-tagged
RUSC2 in starved cells was not altered by the presence of bafi-
lomycin A1, but LC3B-positive puncta accumulated under these
conditions (Supplementary Fig. 9b). To view these structures at
ultrastructural resolution, we performed CLEM of the HeLa
RUSC2-GFP cells grown in starvation conditions in the presence
of bafilomycin A1 (Fig. 9c and Supplementary Fig. 9c). The
RUSC2-GFP signal observed by light microscopy corresponded to
clusters of small, uncoated vesicular structures, as we had pre-
viously observed at the periphery of RUSC2-overexpressing cells
grown in full medium (Fig. 7c). Importantly, we frequently
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Fig. 8 Loss of AP-4 or RUSCs in HeLa cells causes dysregulation of autophagy. a Western blots of whole cell lysates from wild-type and AP4E1 KO HeLa
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loading control. Representative of two independent experiments. b Western blots of whole cell lysates from AP4B1 KO and AP4B1 KO HeLa cells rescued
with stable expression of AP4B1, as described in a. Representative of two independent experiments. cWidefield imaging of wild-type, AP4B1 KO and AP4B1
KO HeLa cells rescued with stable expression of AP4B1, starved for two hours in EBSS, labelled with anti-LC3B. Scale bar: 20 µm. d Quantification of the
apparent size (in µm2) of LC3B puncta using an automated microscope. The experiment was performed in biological triplicate (mean indicated, n= 3), and
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observed double membrane-bound autophagosomes juxtaposed
to the RUSC2-positive vesicle clusters, suggesting that the AP-4-
derived RUSC2- and ATG9A-positive vesicles are the previously
described ATG9A “reservoir” compartment that drives autop-
hagosome biogenesis21.
Discussion
The nature of AP-4 vesicles and their role in membrane traf-
ficking has remained elusive for the two decades since their dis-
covery. Here we have used orthogonal global proteomic tools to
delineate the function of the AP-4 pathway. We identified three
transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3,
and three AP-4 accessory proteins, TEPSIN (which had already
been identified), RUSC1 and RUSC2. Our approach was
hypothesis-free and analysed the subcellular distribution of
endogenous proteins. The latter is critical for assessing the role of
trafficking pathways, especially for AP-4, which is of compara-
tively low abundance. When we overexpressed SERINC3, it was
no longer trafficked in an AP-4-dependent manner (Supple-
mentary Fig. 4e), suggesting that investigations based on over-
expressed candidate cargo proteins are likely to lead to spurious
results. The AP-4-associated proteins identified in this study all
have low expression levels similar to those of AP-4 itself19,
highlighting the sensitivity of our approach. They are also, like
AP-4, expressed ubiquitously. ATG9A localisation depends on
AP-4 not only in HeLa cells, but also in neuroblastoma-derived
SH-SY5Y cells and in fibroblasts from AP-4-deficient patients
(Fig. 3 and Fig. 4), suggesting that trafficking of ATG9A from the
TGN is a ubiquitous function of AP-4. While this manuscript was
in preparation, the Bonifacino lab independently identified
ATG9A as an AP-4 cargo protein33, showing accumulation of
ATG9A at the TGN in AP4E1 knockout HeLa and HAP1 cells,
and mouse embryonic fibroblasts. In further agreement with our
results, they also observed increased levels of ATG9A in AP-4-
deficient cells, increased levels of LC3B and enlarged autopha-
gosomal structures. However, the increased sensitivity of our
proteomic approaches allowed us to reveal additional interactions
between AP-4 and the SERINCs and RUSCs, which were missed
by conventional affinity purification approaches.
Our data strongly support a model whereby AP-4 packages
ATG9A, SERINC1 and SERINC3 into vesicles at the TGN, which
associate via the RUSCs with machinery for microtubule plus-
end-directed transport to the cell periphery (Fig. 10). Addition-
ally, the proximity of these vesicles to autophagosomes in starved
cells (Fig. 9) suggests a role for AP-4-derived vesicles in autop-
hagosome biogenesis, and hence in the spatial control of autop-
hagy. Neuronal deficiency of Atg9a in mice leads to progressive
axonal degeneration, ataxia and convulsions34. Thus, provided
that AP-4 has equivalent functions in neurons and HeLa cells,
which our neuroblastoma data support (Fig. 3d), a hypothesis for
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Fig. 10 Proposed model of AP-4-dependent trafficking. (1) AP-4 and its accessory proteins, TEPSIN, RUSC1 and RUSC2, are recruited to the TGN
membrane where they concentrate their transmembrane cargo proteins, ATG9A, SERINC1 and SERINC3, into a vesicle bud; (2) A vesicle carrying ATG9A
and SERINCs, coated by AP-4 and its accessory proteins, buds from the TGN membrane; (3) AP-4 and TEPSIN fall off the vesicle membrane and are
available for further rounds of vesicle budding at the TGN, while RUSCs remain associated with the vesicle; (4) The vesicle associates with microtubule
transport machinery, via the RUSCs, for plus-end-directed transport to the cell periphery; (5) The peripheral ATG9A-containing vesicles act in the
nucleation of autophagosomes. In neurons, microtubules are polarised with their plus-ends at the distal axon, which is an important site of autophagosome
biogenesis. Thus, in AP-4-deficient neurons ATG9A may not be delivered efficiently to the distal axon, thereby disrupting the spatial control of autophagy
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neuronal AP-4 pathology emerges. Neurons require efficient
long-range transport, especially towards the distal axon, render-
ing them susceptible to disturbances in membrane trafficking35.
Furthermore, microtubules are unipolar in axons, with distally
localised plus-ends36, and the distal axon is an important site of
autophagosome biogenesis37,38. In Caenorhabditis elegans neu-
rons, Atg9-containing vesicles are transported towards the distal
axonal microtubule plus-ends, and this is critical for axonal
autophagosome biogenesis39. Our model suggests that in mam-
malian neurons, AP-4-derived vesicles carrying ATG9A perform
a functionally equivalent role (Fig. 10). In neurons lacking AP-4,
ATG9A will not be packaged correctly at the TGN, and will hence
not efficiently reach the distal axon. This may interfere with
autophagosome formation at the axon terminal and/or with other
functions of ATG9A, disrupting neuronal homoeostasis. This
model is strongly supported by further work from the Bonifacino
lab40, published during the revision of this manuscript, and by a
preprint from the Kittler lab41, both of which characterise an
Ap4e1 knockout mouse. The mice exhibit a number of neurolo-
gical motor deficits and brain abnormalities reminiscent of those
observed in AP-4-deficient patients. Both groups independently
reported an accumulation of Atg9a at the TGN of primary neu-
rons from the Ap4e1-deficient mice, distal axonal swellings, and
reduced retrograde movement of autophagosomes, suggesting a
defect in autophagosome maturation40,41.
The identification of ATG9A as an AP-4 cargo, by our lab and
others33,40,41, provides a potential mechanistic basis for the
aberrant accumulation of autophagosomes previously observed in
neuronal axons of Ap4b1 knockout mice11. There is a similar
dysregulation of autophagy in AP-4 knockout HeLa cells, which
contain enlarged autophagosomes and increased levels of LC3B
(Fig. 8). Basal elevation of LC3B-I and LC3B-II has been observed
in ATG9A knockout HeLa cell lines42–44, so our data are con-
sistent with the notion of ATG9A mistrafficking leading to
impaired ATG9A function. The role of ATG9A in autophagy is
poorly defined, but it is thought to contribute to autophagosome
nucleation, without becoming incorporated into the autophago-
some membrane itself21,45. In yeast the phagophore assembly site
originates from Atg9-positive clusters of vesicles and tubules (the
“Atg9 reservoir”)46. Likewise, in mammalian cells Atg9 localises
to a tubulovesicular compartment, distinct from other organellar
markers21. The AP-4-derived ATG9A-positive vesicles and
tubules we have observed at the periphery of RUSC2-
overexpressing cells fit published descriptions of this compart-
ment21,46–48 (Fig. 7c). Furthermore, under conditions of starva-
tion these vesicles are found in close proximity to
autophagosomes (Fig. 9c), supporting a role in autophagosome
biogenesis. In AP-4-deficient cells, ATG9A trafficking may be
stalled at the TGN and the peripheral “ATG9A reservoir”
depleted. Further investigation is necessary to understand how
this may lead to the observed effects on autophagosomes in AP-4-
deficient cells. ATG9A mistrafficking has been linked previously
to an accumulation of enlarged immature autophagosomes in
Niemann-Pick type A patient fibroblasts49. The increased size of
LC3B puncta in our AP-4 knockout HeLa cells may point to a
similar maturation defect, and future CLEM analysis will be
important to investigate this further. Finally, it is worth noting
that ATG9A has functions independent of autophagy34,50,51,
which may also be relevant to potential pathogenic effects caused
by its missorting.
Loss-of-function mutations in RUSC2 cause a neurological
disorder with considerable overlap with the AP-4 deficiency
phenotype23. This is in keeping with our identification of RUSCs
as AP-4 accessory proteins and the very similar effects of AP-4
and RUSC2 depletion on autophagy (Fig. 8). The additive effect
of RUSC1 and RUSC2 combined knockdown suggests partial
functional redundancy and links them both clearly to the AP-4
trafficking pathway. Given the role of RUSCs in the subcellular
distribution of ATG9A, and hence in the regulation of autophagy,
it will be important to further investigate their function, and to
identify additional machinery involved. Furthermore, it will be
interesting to look for similar ATG9A and SERINC sorting
defects in cells from RUSC2-deficient patients. The RUSCs are
poorly characterised but implicated in vesicular transport31,52.
RUSC1 has been proposed to act as a vesicle-transport adaptor by
linking syntaxin-1 to kinesin-1 motors31. Our data suggest that
the RUSCs may similarly link AP-4 vesicles to microtubule
transport machinery (Fig. 7).
The presence of SERINC1 and SERINC3 in the ATG9A
tubulovesicular compartment also warrants further investigation.
Whereas previous studies have relied on overexpressed tagged
SERINC proteins for localisation53,54,56, here we show their
endogenous subcellular localisation. Little is known about the
function of SERINCs, despite their recent identification as HIV
restriction factors53–55 and their high degree of conservation in all
branches of eukaryotes. They were originally proposed to mediate
the incorporation of serine into membrane lipids56, but recent
functional studies have shown no effect on membrane composi-
tion57,58. Our discovery that ATG9A and SERINCs are trafficked
together suggests a functional relationship.
In conclusion, this study has greatly expanded our under-
standing of the AP-4 pathway and provides strong evidence that
AP-4-derived vesicles play an important role in the spatial control
of autophagy. The identification of AP-4 cargo and accessory
proteins provides tools for further investigation of AP-4 function,
generates hypotheses about the pathomechanism of AP-4 defi-
ciency, and marks a significant step towards the development of
possible treatments.
Methods
Antibodies. The following antibodies were used in this study: rabbit anti-actin
1:3000 for WB (A2066, Sigma-Aldrich), mouse anti-alpha tubulin 1:10,000 for WB
(DM1A, T9026, Sigma-Aldrich), rabbit anti-AP4B1 1:400 for WB, rabbit anti-
AP4E1 1:1000 for WB (both in-house3), mouse anti-AP4E1 1:100 for IF (612019;
BD Transduction Labs), rabbit anti-ATG9A 1:1000 for WB and 1:100 for IF
(ab108338, Abcam), mouse anti-CIMPR 1:200 for IF (ab2733, Abcam), rabbit anti-
clathrin heavy chain 1:10,000 for WB (in-house59), mouse anti-EEA1 1:500 for IF
(610457, BD Transduction Labs), rabbit anti-GFP 1:500 for IF (gift from Matthew
Seaman, University of Cambridge), rabbit anti-GFP 1:1000 for WB (ab6556,
Abcam), chicken anti-GFP 1:500 for IF (ab13970, Abcam), mouse anti-HA 1:2000
for WB and IF (16B12, Covance), mouse anti-LAMP1 1:100 for IF (H4A3, Santa
Cruz Biotechnology), rabbit anti-LC3B 1:2000 for WB (L7543, Sigma-Aldrich),
mouse anti-LC3B 1:400 for IF (M152-3, MBL International), rabbit anti-TEPSIN
1:1000 for WB and 1:250 for IF (in-house18), and sheep anti-TGN46 1:200 for IF
(AHP500, Bio-Rad). Horseradish peroxidase (HRP)-conjugated secondary anti-
bodies were purchased from Sigma-Aldrich (1:10,000). Fluorescently labelled sec-
ondary antibodies used in this study were Alexa488-labelled goat anti-chicken IgY
(A11039), Alexa488-labelled donkey anti-mouse IgG (A21202), Alexa555-labelled
donkey anti-mouse IgG (A31570), Alexa568-labelled goat anti-mouse IgG
(A11031), Alexa594-labelled donkey anti-mouse IgG (A21203), Alexa488-labelled
donkey anti-rabbit IgG (A21206), Alexa555-labelled goat anti-rabbit IgG (A21429),
Alexa594-labelled donkey anti-rabbit IgG (A21207), Alexa647-labelled donkey
anti-rabbit IgG (A31573), Alexa488-labelled donkey anti-sheep IgG (A11015),
Alexa594-labelled donkey anti-sheep IgG (A11016), and Alexa680-labelled donkey
anti-sheep IgG (A21102), all purchased from Invitrogen and used at 1:500.
Constructs. A modified retroviral pLXIN vector (pLXINmod) was a gift from
Andrew Peden (University of Sheffield). Myc-BirA* cDNA was amplified from
pcDNA3.1_mycBioID (a gift from Kyle Roux; Addgene plasmid #3570024) by PCR.
AP4B1 cDNA was amplified from a full-length IMAGE clone (2906087), AP4E1
cDNA from a full-length IMAGE clone (40146497), and AP4M1 and AP4S1
cDNAs from sequence verified EST clones. For generation of the AP-4 knock-
sideways construct, a sequence encoding the FKBP domain22 preceded by a short
linker sequence (GALVNGGPEPAKNLYT) was cloned into the natural Sac1 site of
the AP4E1 cDNA in vector pLXINmod, to introduce FKBP into the flexible hinge
region of AP4E1 between residues 730 and 731. The control BioID construct,
pEGFP-myc-BirA*, was made by cloning myc-BirA* cDNA into a pEGFP-N2
vector (Clontech) using BsrGI and XbaI restriction sites. The AP4E1 BioID
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construct was made using Gibson Assembly Master Mix (E2611, New England
BioLabs) to introduce myc-BirA* into the flexible hinge region of AP4E1, between
residues 730 and 731, inserted into the pLXINmod vector linearised with an HpaI
restriction site. AP4E1 cDNA was amplified as two separate fragments from the
AP4E1_FKBP construct described above, including the linker sequence so that it
precedes myc-BirA* in the final construct. For AP4B1, AP4M1 and AP4S1 BioID
constructs, a C-terminal myc-BirA* tagging construct was used. This was generated
using Gibson Assembly to introduce myc-BirA*, preceded by a glycine-serine
linker (10 amino acids) and an upstream BglII site, into the HpaI site of pLXIN-
mod. The BglII site was used to linearise the myc-BirA* tagging construct and
cDNAs for AP4B1/M1/S1 were added by Gibson Assembly. RUSC2 cDNA was
amplified from pCMV-SPORT6_RUSC2 (MHS6278-202800194, Thermo Fisher
Scientific) and GFP cDNA was amplified from pEGFP-N2. Constructs for stable
overexpression of GFP-tagged RUSC2, pQCXIH_GFP-RUSC2 and pQCXIH_-
RUSC2-GFP, were generated using Gibson Assembly to introduce RUSC2 and GFP
cDNAs into the retroviral vector pQCXIH (Clontech). The AgeI site of pQCXIH
was used for GFP-RUSC2 and the NotI site for RUSC2-GFP. pQCXIH_HA-
RUSC2 was made by cutting out GFP from pQCXIH_GFP-RUSC2 with NotI and
AgeI restriction sites and replacing it with a triple HA tag. SERINC3 cDNA was
amplified from pIRESNeo2_SERINC3-HA-mCherry, a custom synthetic construct
(Genecust) based on the SERINC3 clone AAD22448.1, with several silent nucleo-
tide substitutions. The construct for stable overexpression of HA-tagged SERINC3,
pLXIN_SERINC3_HA, was made using Gibson Assembly to introduce an HA tag
between residues 311 and 312 of SERINC3 (within an extracellular loop), inserted
into the pLXINmod vector linearised with HpaI. The sequences of all constructs
described here were verified by Sanger DNA sequencing. See Supplementary
Methods for a complete list of the PCR primers used.
Cell culture. HeLa M cells and HEK 293ET cells were from ECACC and the
human neuroblastoma cell line SH-SY5Y60 was from Sigma-Aldrich. The HeLa
cells stably expressing BirA* were a gift from Folma Buss (University of Cam-
bridge) and the HeLa cells stably expressing EGFP were a gift from Matthew
Seaman (University of Cambridge). The HeLa cells stably expressing TEPSIN-GFP
used for the conventional and sensitive immunoprecipitations had previously been
generated in our laboratory18. The AP4B1 knockout HeLa cells (clone x2A3) and
wild-type β4 rescued AP4B1 knockout HeLa cells were previously described26. The
human fibroblasts from AP-4 deficient patients have been previously described and
reduced AP-4 complex formation has been demonstrated for all patient lines.
Molecular details of mutations and references for each are as follows: AP4B1*,
GenBank NM_006594: c.487_488insTAT, p.Glu163_Ser739delinsVal5,18 (a gift
from Laurence Colleaux, Institut Imagine, and Annick Raas-Rothschild, Tel Aviv
University); AP4E1*, GenBank NM_007347: c.3313C>T, p.Arg1105*29 (a gift from
Xiao-Fei Kong, Jean-Laurent Casanova, and Stephanie Boisson-Dupuis, The
Rockefeller University); AP4M1*, GenBank NM_004722: c.1137+1G>T, p.
Ser342ArgfsTer656,18 (a gift from Grazia Mancini, Erasmus Medical Center);
AP4S1*, GenBank NM_007077: c.[289C>T];[138+3_6delAAGT], p.[Arg97*];[?]30
(the second mutation, which is at a splice donor site, was originally inaccurately
reported as c.138_140delAATG). The control fibroblasts (from a healthy control
donor) were a gift from Craig Blackstone (NIH) and the heterozygous AP4E1WT/
AP4E1* fibroblasts (a gift from Kong et al. as above) were from the unaffected
mother of the homozygous AP4E1* patient.
HeLa M cells were maintained in RPMI 1640 (R0883, Sigma-Aldrich). SH-
SY5Y cells and human fibroblasts were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) high glucose (D6546, Sigma-Aldrich). All media was
supplemented with 10% v/v foetal calf serum, 4 mM L-glutamine, 100 UmL−1
penicillin and 100 µg mL−1 streptomycin and all cells were cultured at 37 °C under
5% CO2. Stable cell lines were additionally maintained with 500 µg mL−1 G418 or
150 μg mL−1 hygromycin as appropriate. For metabolic labelling (SILAC
method61) in most experiments, HeLa cells were cultured in DMEM without
Arginine, Glutamine, Lysine or Sodium Pyruvate (A14431-01, Gibco),
supplemented with 10% (v/v) dialysed foetal calf serum (A11-107, PAA), 1 mM
Sodium Pyruvate (58636, Sigma-Aldrich), 1x GlutaMAX (35050-061, Gibco), and
either “Heavy” amino acids (42 mg L−1 13C6, 15N4-L-Arginine HCl and 73 mg L−1
13C6, 15N2-L-Lysine HCl; 201604302 and 211604302, Silantes), or the equivalent
“Light” amino acids (Arginine HCl [A6969] and Lysine HCl [L8662], Sigma-
Aldrich). Cells were cultured for at least seven days in these media before
experiments were performed. In the vesicle fraction experiments, metabolic
labelling was performed in SILAC RPMI 1640 medium (89984, Thermo Fisher
Scientific), supplemented with 10% (v/v) dialysed foetal calf serum (10,000MW
cut-off; Invitrogen), and either “Heavy” amino acids (50 mg L−1 13C6, 15N4-L-
Arginine HCl and 100 mg L−1 13C6, 15N2-L-Lysine 2HCl; Cambridge Isotope
Laboratories), or the equivalent “Light” amino acids.
Transient DNA transfections were carried out using a TransIT-
HeLaMONSTER® kit (Mirus Bio LLC), according to the manufacturer’s
instructions. Stable cell lines were created using retrovirus made in HEK
293ET cells transfected using TransIT-293 Transfection Reagent (Mirus Bio LLC),
according to the manufacturer’s instructions. pLXIN or pQCXIH plasmids were
mixed with the packaging plasmids pMD.GagPol and pMD.VSVG in a ratio of
10:7:3. Viral supernatants were harvested after 48 h, filtered through a 0.45 µm
filter, supplemented with 10 µg mL−1 hexadimethrine bromide (Polybrene, Sigma-
Aldrich) and applied directly to the target cells at 37 °C. Antibiotic selection for
stable expression (500 µg L−1 G418 or 150 μg mL−1 hygromycin) was initiated 48 h
post-transduction. When necessary due to variable levels of transgene expression in
mixed populations of stably transduced cells, cell lines were single cell cloned by
serial dilution. For generation of the AP-4 knocksideways cell line, the AP4E1-
FKBP construct was introduced into HeLa cells stably expressing a mitochondrially
targeted bait (Mito-YFP-FRB22), using retrovirus as described above. Clonal cell
lines were isolated and selected for appropriate expression levels. Correct
localisation of the AP4E1-FKBP and rapamycin-induced rerouting of AP-4 to
mitochondria were verified by microscopy. HeLa cells stably overexpressing
SERINC3-HA-mCherry were generated by plasmid (pIRESNeo2_SERINC3-HA-
mCherry) transfection and antibiotic selection in G418. A mixed population of
medium-level overexpressing cells was obtained through FACS. Importantly, due
to the overexpression, the subcellular sorting of tagged SERINC3 is no longer
dependent on AP-4 in these cells (Supplementary Fig. 4e).
Where indicated cells were treated with 10 μg mL−1 nocodazole in cell culture
medium for 2 h at 37 °C. For starvation during autophagy assays, cells were washed
three times with Earle’s balanced salt solution (EBSS; Sigma-Aldrich) and
incubated in EBSS for the specified time. Where indicated cells were treated with
100 nM Bafilomycin A1 in cell culture medium or EBSS for 2 h. For AP-4
knocksideways, cells were treated with rapamycin at 200 ng mL−1 final
concentration (from a 1mgmL−1 stock in ethanol) for 60 min.
No cell lines used in this study were found in the database of commonly
misidentified cell lines that is maintained by ICLAC and NCBI Biosample. The cell
lines were routinely tested for the presence of mycoplasma contamination using
DAPI to stain DNA and were regularly treated with mycoplasma removing agent
(093050044, MP Biomedicals).
CRISPR/Cas9-mediated gene editing. The Zhang online CRISPR design tool
(http://crispr.mit.edu/62) was used to identify suitable gRNA targets. gRNAs were
ordered as pairs of complementary oligos (Sigma-Aldrich) with the sequences 5′-
CACCGN20-3′ and 5′-AAACN20C-3′, which were annealed and cloned into the
BbsI site of the appropriate Cas9/gRNA delivery vector.
For the AP4E1 knockout HeLa cell line we inactivated all copies of the AP4E1
gene using the ‘double nickase’ CRISPR/Cas9 system63,64. Paired gRNAs targeting
exon 6 of AP4E1 (ENST00000261842: CTTGATTAGGAGCAATGAGA and
GCACTTTGTGACAGAGATGT) were individually cloned into pX335-U6-
Chimeric_BB-CBh-hSpCas9n(D10A) vectors (a gift from Feng Zhang; Addgene
plasmid #4233563). HeLa M cells were transfected with both pX335 plasmids and
pIRESpuro (Clontech) in a ratio of 2:2:1. Forty-eight hours later, untransfected cells
were killed off by a 4-day selection in 1 µg mL−1 puromycin. Single cell clones were
isolated and tested for knockout of AP4E1 by Western blotting and
immunofluorescence. Clone x6C3 was negative for AP4E1 expression in both
assays and was further validated by sequencing. Genomic DNA was harvested
using a High Pure PCR Template Purification Kit (Roche) and PCR was used to
amplify the region around the target sites. The PCR products were then blunt-end
cloned (Zero Blunt PCR Cloning Kit; Invitrogen) and 17 clones were sent for
Sanger sequencing with the M13_F primer (Beckman Coulter Genomics).
For depletion of AP4B1 and AP4E1 in SH-SY5Y cells, a lentiviral CRISPR/
Cas9 system was used65. Lentivirus was produced by transfecting HEK 293ET cells
with the lentiviral vector plus the packaging plasmids pCMVΔR8.91 and pMD.G in
a ratio of 10:7:3, using TransIT-293 Transfection Reagent. Harvest of viral
supernatants, lentiviral transductions and selection for stable expression (150 μg
mL−1 hygromycin or 3 μg mL−1 puromycin) were performed as described above
for retroviral transductions. Wild-type Cas9 was stably introduced into SH-SY5Y
cells using the lentiviral vector pHRSIN-PSFFV-FLAG-Cas9-PPGK-Hygro (a gift
from Paul Lehner, University of Cambridge). Cas9-expressing SH-SY5Y cells were
then transduced with gRNAs targeting exon 2 of AP4B1 (ENST00000369569.5:
GACCCCAATCCAATGGTGCG) or exon 6 of AP4E1 (ENST00000261842.9:
GCACTTTGTGACAGAGATGT), cloned into the lentiviral sgRNA expression
vector pKLV-U6gRNA(BbsI)-PGKpuro2ABFP (a gift from Kosuke Yusa; Addgene
#5094666). Mixed populations of cells were selected for stable expression of Cas9
and gRNA and knockouts were assessed at the protein level by Western blotting.
For CRISPR/Cas9-mediated endogenous tagging of SERINC1 and SERINC3, we
used homology-directed repair to introduce a myc-Clover tag at the C-terminus of
each protein. Suitable sgRNA targets were selected to enable Cas9 to cut
downstream and proximal to the STOP codon of SERINC1 (ENST00000339697.4:
ATACACAACTTTACAAAAGT) and SERINC3 (ENST00000342374.4:
GGTATATGGGTTTTCGGTGA). gRNAs were cloned into pX330-U6-
Chimeric_BB-CBh-hSpCas9 vectors (a gift from Feng Zhang; Addgene plasmid
#4223063), containing cDNA for wild-type Cas9. To generate the homology-
directed repair plasmids we made use of a pDonor_myc-Clover plasmid which was
a gift from Dick van den Boomen and Paul Lehner (University of Cambridge). This
was created using a plasmid gifted to them by Matthew Porteus and Ron Kopito
(Stanford University), originally containing a TAP-tag, which was replaced with
myc-Clover cloned from pcDNA3.1-Clover-mRuby2 (a gift from Kurt Beam;
Addgene #4908967). pDonor_myc-Clover contains a 5’ homology region, followed
by myc-Clover, an internal ribosome entry site, a puromycin resistance gene and
then a 3' homology region. The existing homology regions were replaced by Gibson
Assembly with regions specific for SERINC1 (ENSG00000111897: 5′ – 806 bp
preceding the STOP codon; 3′ – 814 bp starting 161 bp after the STOP codon) or
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SERINC3 (ENSG00000132824: 5′ – 835 bp preceding the STOP codon; 3′ – 817 bp
starting 95 bp after the STOP codon). 3′ homology regions were chosen to avoid
the gRNA target sites. The primers used to clone the homology regions are
provided in Supplementary Methods. HeLa M cells were transfected with the
pX330 and pDonor plasmids in a ratio of 1:1. Forty-eight hours later selection for
stable expression of the puromycin resistance gene (meaning incorporation of the
Clover tag) was initiated. Single cell clones were isolated and tested for knock-in of
Clover by Western blotting and immunofluorescence with an anti-GFP antibody.
Clones SERINC1-Clover A3 and SERINC3-Clover B6 were positive for Clover
expression in both assays and correct integration of the tag was confirmed by
Sanger DNA sequencing.
siRNA-mediated knockdown. Knockdown of AP-4 was achieved by combined
siRNA targeting of AP4E1 and AP4M1 using ON-TARGETplus SMARTpools
(AP4E1, L-021474-00; AP4M1, L-011918-01; Dharmacon), using a double-hit 96 h
protocol18. For the first hit the final concentration of siRNA was 40 nM (20 nM
AP4M1+ 20 nM AP4E1). The second hit was performed 48 h after the first hit with
half the final concentration of siRNA. For knockdown of RUSC1 an ON-
TARGETplus SMARTpool (L-020607-01, Dharmacon) was used. For knockdown
of RUSC2 two independent GeneSolution siRNAs (Hs_RUSC2_4, SI00709128;
Hs_RUSC2_7, SI04296264; Qiagen) were used, resulting in similar knockdown
efficiencies at the mRNA level and highly similar phenotypes in our LC3B Western
blot assay. For clarity, only the data for one oligo (Hs_RUSC2_4) is shown in Fig. 8,
but the Western blot for Hs_RUSC2_7 can be seen in the uncropped scan of the
blot shown in Supplementary Fig. 11. For the RUSC knockdowns a double-hit 72 h
protocol was used with a final siRNA concentration of 20 nM for the first hit and
10 nM for the second hit, performed 36 h later. For the combined RUSC1 and 2
knockdowns the final concentration of siRNA was 20 nM for each gene (10 nM for
the second hit). Transfections of siRNA were carried out with Oligofectamine
(Thermo Fisher Scientific), according to the manufacturer′s instructions and where
indicated cells were mock treated with Oligofectamine without siRNA or trans-
fected with ON-TARGETplus Non-targeting siRNA #1 (D-001810-01, Dharma-
con). Three independent experiments were performed, unless otherwise noted in
the figure legend.
Quantitative RT-PCR. For quantitative RT-PCR analysis, total RNA was extracted
from around 5 × 105 cells using an RNeasy Mini Kit (Qiagen) with on-column
DNase digestion using an RNase-Free DNase Set (Qiagen), according to the
manufacturer’s instructions. A total of 500 ng of total RNA was reverse-transcribed
using TaqMan® Reverse Transcription Reagents (Thermo Fisher Scientific) in a 20
μL reaction, according to the manufacturer’s instructions. Quantitative-PCR was
performed using TaqMan® gene expression assays (Thermo Fisher Scientific),
which include two unlabelled PCR primers and one FAM® dye-labelled TaqMan®
MGB probe, according to the manufacturer’s instructions; TaqMan® Assay IDs
were Hs00204904_m1 for RUSC1 and Hs00922017_m1 for RUSC2. The cDNA was
diluted 1:5, and 5 μL of this dilution (25 ng RNA equivalent) was used for each
PCR reaction using TaqMan® Universal PCR Master Mix (Thermo Fisher Scien-
tific) and using a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific),
with Standard mode thermal cycling conditions. Every reaction was carried out in
technical triplicate and each knockdown was performed in biological triplicate. For
each sample, the levels of RUSC1 and RUSC2 mRNAs were normalised using
GAPDH as a loading control (TaqMan® Assay ID Hs99999905_m1; Thermo Fisher
Scientific). The data were analysed in Microsoft Excel using the ΔΔCt method,
relative to a non-targeting siRNA control. Results are expressed as means ± SEM
for each biological triplicate.
Fluorescence microscopy. Cells were grown onto 13 mm glass coverslips and
fixed in 3% formaldehyde in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4
and 1.76 mM KH2PO4, pH 7.4) or, for AP4E1 labelling, ice-cold methanol. For-
maldehyde fixed cells were permeabilised with 0.1% saponin and blocked in 1%
BSA/0.01% saponin in PBS. Methanol fixed cells were blocked in 0.5% BSA. Pri-
mary antibody (diluted in BSA block) was added for 45 min at room temperature.
Coverslips were washed three times in BSA block and then fluorochrome-
conjugated secondary antibody was added in block for 30 min at room tempera-
ture. Coverslips were then washed three times in PBS, followed by a final wash in
dH2O, before being mounted in ProLong Diamond Antifade Reagent with DAPI
(Thermo Fisher Scientific). Widefield images were captured on an Axio Imager II
microscope (63×/1.4 NA oil immersion objective; AxioCam 506 camera; ZEISS)
and confocal and Airyscan enhanced resolution images were captured on an
LSM880 confocal microscope with Airyscan (63×/1.4 NA oil immersion objective;
ZEISS), both equipped with ZEN software (ZEISS). Airyscan images were taken in
SR (super resolution) mode and raw data were processed using Airyscan processing
in “auto strength” mode (strength= 6.0) with Zen Black software version 2.3.
Quantification of SERINC1/3-Clover and ATG9A colocalisation was performed on
Airyscan images. Colocalisation was measured using Pearson’s Correlation Coef-
ficient with Costes thresholding method (Volocity software 6.3; Perkin Elmer), in a
peripheral 10 μm2 area in each cell, selected while viewing the green channel only.
A minimum of 19 cells were analysed for each condition. For statistical analysis
data were analysed by a two-tailed Mann–Whitney U-test.
For automated imaging of ATG9A localisation and LC3B puncta, cells were
plated in 96-well microplates (6005182, Perkin Elmer), which were either uncoated
or for the LC3B assay coated with poly-D-lysine. Cells were fixed in 3%
formaldehyde in PBS, permeabilised with 0.1% saponin and labelled for
immunofluorescence as described above. After washing off secondary antibody,
cells were stained with HCS CellMask™ Blue stain (Thermo Fisher Scientific)
diluted 1:5000 in PBS for 30 min at room temperature. Cells were then washed
three times in PBS before imaging using a CellInsight CX7 High-Content Screening
Platform (Olympus 20×/0.4NA objective; Thermo Fisher Scientific) running HCS
StudioTM 3.0 software. Autofocus was applied using the whole cell mask channel
(channel 1). Experiments were performed in biological triplicate with a technical
triplicate (three separate wells per cell line) within each experiment. ATG9A
localisation was quantified using the Colocalization Bioapplication V4 (Cellomics,
Thermo Fisher Scientific), using anti-TGN46 to segment the TGN (channel 2;
ROI_B). ROI_A was defined by the whole cell mask (channel 1) minus ROI_B. The
average intensity of anti-ATG9A (channel 3; target 1) was then quantified in the
two regions and a ratio calculated between the two. Ratios were normalised to the
mean wild-type ratio. At least 1400 cells were scored per cell line in each
experiment. For statistical analysis data were log transformed and analysed by one-
way ANOVA with Dunnett’s Multiple Comparison Test. LC3B puncta were
quantified using the Spot Detector Bioapplication V4 (Cellomics, Thermo Fisher
Scientific). Spots were identified with smoothing on (uniform; value= 1), with the
detection method Box (value= 1) and ThreeSigma thresholding (value= 0.012).
Spot total count and average area (in μm2) were measured. At least 500 cells were
scored per cell line in each experiment. For statistical analysis data were analysed
by one-way ANOVA with Dunnett’s Multiple Comparison Test.
Where representative images are shown, the experiment was repeated at least
two times. Statistical analyses of imaging data were performed using GraphPad
Prism version 5.01 (GraphPad Software).
Correlative light and electron microscopy (CLEM). HeLa GFP-RUSC2 (clone 3)
cells were mixed with wild-type HeLa cells and seeded on alpha-numeric gridded
glass-bottom coverslips (P35G-1.5-14-C-GRID, MatTek) to be 40–50% confluent
at the time of fixation. Cells were fixed with 2% formaldehyde/2.5% glutaraldehyde/
0.1 M cacodylate buffer for 30 min at room temperature and washed with 0.1 M
cacodylate. Cells were then stained with Hoechst (to stain the nucleus) for 2 min,
before being washed with 0.1 M cacodylate. GFP-RUSC2 fluorescence signal was
imaged on an LSM780 confocal microscope (63×/1.4 NA oil immersion objective;
ZEISS) and the coordinates of cells selected for imaging were recorded. To prepare
for electron microscopy cells were secondarily fixed with 1% osmium tetroxide/
1.5% potassium ferrocyanide and then incubated with 1% tannic acid in 0.1 M
cacodylate to enhance membrane contrast. Samples were washed with dH2O and
dehydrated using increasing concentrations of ethanol. Epoxy resin (Araldite
CY212 mix, Agar Scientific) was mixed at a 1:1 ratio with propylene oxide and this
was used for 1 h to infiltrate the samples with resin, following which it was replaced
with neat Epoxy resin. Pre-baked resin stubs were inverted over coordinates of
interest, resin was cured overnight at 65 °C, following which stubs were removed
from coverslips using liquid nitrogen. Areas of interest were identified by alpha-
numeric coordinates and 70 nm ultrathin sections were collected using a Diatome
diamond knife attached to an ultracut UCT ultramicrotome (Leica). As areas of
interest were at the very basal surfaces of cells (and so the very top of the resin
stub), sections were immediately collected onto piloform-coated slot grids. Sections
were stained with lead citrate before being imaged on a Tecnai Spirit transmission
electron microscope (FEI) at an operating voltage of 80 kV. HeLa GFP-RUSC2 and
wild-type cells were imaged, and peripheral accumulations of uncoated vesicular
and tubular structures were only observed in the regions of HeLa GFP-RUSC2 cells
that correlated with the GFP fluorescence.
For the CLEM analysis of RUSC2 overexpressing cells in starvation conditions,
HeLa RUSC2-GFP (clone 1) cells were seeded on alpha-numeric gridded glass-
bottom coverslips, as above, and incubated in EBSS with 100 nM Bafilomycin A1
for 2 h before fixation. All other steps were performed as described above.
Western blotting. Estimations of protein concentrations were made using a Pierce
BCA Protein Assay Kit (Thermo Fisher Scientific). Cells were lysed for Western
blot analysis in 2.5% (w/v) SDS/50 mM Tris pH 8. Lysates were passed through a
QIAshredder column (Qiagen) to shred DNA, incubated at 65 °C for 3 min and
then boiled in NuPAGE LDS Sample Buffer (Thermo Fisher Scientific). Samples
were loaded at equal protein amounts for SDS-PAGE, performed on NuPAGE
4–12% Bis–Tris gels in NuPAGE MOPS SDS Running Buffer, or for LC3B blots, on
NuPAGE 12% Bis–Tris gels in NuPAGE MES SDS Running Buffer (all Thermo
Fisher Scientific). PageRuler Plus Prestained Protein Ladder (Thermo Fisher Sci-
entific) was used to estimate the molecular size of bands. Proteins were transferred
to nitrocellulose membrane by wet transfer and membranes were blocked in 5% w/
v milk in PBS with 0.1% v/v Tween-20 (PBS-T). Primary antibodies (diluted in 5%
milk) were added for at least 1 h at room temperature, followed by washing in PBS-
T, incubation in secondary antibody (also in 5% milk) for 30 min at room tem-
perature, washing in PBS-T and finally PBS. Chemiluminescence detection of HRP-
conjugated secondary antibody was carried out using Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare) and X-ray film. Where
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06172-7
16 NATURE COMMUNICATIONS |  (2018) 9:3958 | DOI: 10.1038/s41467-018-06172-7 | www.nature.com/naturecommunications
representative blots are shown, the experiment was repeated at least two times.
Uncropped scans of all blots are shown in Supplementary Fig. 10–12.
Protein expression and purification for GST pulldowns. Human AP4E1 (resi-
dues 881–113518) and AP4B1 (residues 612–73926) appendage domains were
expressed as GST-fusion proteins in BL21(DE3)pLysS cells (Invitrogen) for
16–20 h at 22 °C after induction with 0.4 mM IPTG. Proteins were purified in
20 mM HEPES pH 7.5, 200 mM NaCl, and 2 mM 2-Mercaptoethanol. Cells were
lysed using a disruptor (Constant Systems Limited) and proteins were affinity
purified using glutathione sepharose (GE Healthcare). Fusion proteins were eluted
in buffer with 30 mM reduced glutathione and further purified by gel filtration on a
Superdex S200 preparative column (GE Healthcare).
GST pulldowns from cytosol. All steps were performed on ice with pre-chilled
ice-cold buffers, unless otherwise noted.
To prepare cytosol for pulldowns, HeLa cells stably expressing EGFP or GFP-
RUSC2 (clone 3), each in two 15 cm plates, were washed in PBS and then cytosol
buffer (20 mM HEPES pH 7.5, 150 mM NaCl) and scraped in a total volume of 800
µL cytosol buffer plus 2 mM DL-Dithiothreitol (DTT, D5545, Sigma Aldrich). Cells
were transferred to a 1 mL Dounce homogeniser (Wheaton) and homogenised with
15 strokes with the tight pestle, followed by 10 passes through a 30.5 gauge needle.
Homogenates were then centrifuged at 78,400×g (RCF max) in a TLA-110 rotor
(Beckman Coulter) for 30 min to pellet cell debris and the supernatants (cytosol)
transferred to new tubes, snap frozen in liquid nitrogen, before storage at −80 °C
until use in the pulldown assay.
For the pulldowns with AP-4 appendage domains, glutathione sepharose 4B
(GE Healthcare) resin was batch equilibrated with 20 mM HEPES pH 7.5, 150 mM
NaCl, 2 mM DTT. The 50% resin slurry (60 µL) was incubated and rotated with 50
µg of GST, GST-AP4E1, or GST-AP4B1 appendage for 1 h at 4 °C. Equal total
protein amounts of HeLa lysates containing GFP-RUSC2 were added
independently to each bait sample. Samples were incubated and rotated for 1 h at
4 °C. Samples were centrifuged at 2500×g for 5 min. Supernatant was removed, and
resin was washed with 1 mL of wash buffer (20 mM HEPES pH 7.5, 150 mM NaCl,
2 mM DTT, 0.5% NP-40) for a total of three washes. After final removal of
supernatant, 65 μL elution buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM
DTT, 60 mM reduced glutathione) were added to each sample and incubated for
10 min at 4 °C. Samples were centrifuged at 5000×g for 5 min, then supernatant
was removed and transferred to a new tube. 10 μL fresh 1M DTT and 25 μL SDS
loading dye were added, and samples were boiled at 95 °C for 10 min. Control
HeLa lysates containing GFP were treated in the same way as a control.
Immunoprecipitations. All steps were performed on ice with pre-chilled ice-cold
buffers, unless otherwise noted.
For sensitive immunoprecipitation of TEPSIN-GFP, wild-type HeLa cells
(control) and HeLa cells stably expressing TEPSIN-GFP18 were grown in SILAC
media. For two biological replicates (data shown in Fig. 2f) the wild-type cells were
heavy labelled and the TEPSIN-GFP cells light labelled. A third replicate was
performed with a label swap and used to filter out unlabelled proteins from the
data. For each cell line, two 100 mm plates were washed once in PBS (without
CaCl2 and MgCl2; 14190–094, Thermo Fisher Scientific) and then scraped in 4 mL
PBS. Cells were transferred to a Dounce homogeniser (Sartorius) and homogenised
with 20 strokes with the tight pestle, followed by two passes through a 21 gauge
needle. Triton-TX-100 was added to the cells to a final concentration of 0.01%, cells
were incubated at 4 °C for 20 min with rotation, and homogenates were cleared by
centrifugation at 4000×g for 10 min. A portion of each homogenate was retained as
input and the remainder was incubated with GFP-Trap A beads (ChromoTek) at
4 °C for 3 h with rotation. Beads were washed five times with 0.01% Triton-TX-100
and then immunoprecipitates were eluted in 100 μl 2.5% (w/v) SDS/50 mM Tris
pH 8 and heated at 65 °C for 5 min. Beads were pelleted and supernatants
(immunoprecipitates) transferred to new tubes. Equal volumes of control and
TEPSIN-GFP immunoprecipitates were mixed and in-solution tryptic digest and
peptide purification (single shot) were performed as described below.
For conventional immunoprecipitation68, wild type or TEPSIN-GFP expressing
cells18 were SILAC labelled (in biological duplicate, with label-swap). For
harvesting, cells from 2 × 500 cm2 dishes (per IP) were washed twice in PBS,
scraped into 10 mL of PBS-TT (PBS, 0.2% (v/v) Triton X-100, 0.1% (v/v) Tween-
20), and incubated for 25 min with rotation. Insoluble material was removed by
centrifugation at 4800×g for 3 min, followed by centrifugation at 21,000×g for 20
min. The supernatant was then further cleared by filtration through a 0.22 μm
syringe filter. Lysates were pre-absorbed against Protein A sepharose beads.
Approximately 60 μg of rabbit polyclonal anti-GFP antibody (a gift from Matthew
Seaman) was added to cleared lysates. After incubation at 4 °C for 90 min with
rotation, 50 μl of Protein A sepharose beads were added, and samples were
incubated for a further 45 min. Beads were washed four times in PBS-T, once in
PBS, and immunoprecipitates recovered in 100 µL Soft Elution Buffer (0.2% (w/v)
SDS, 0.1% (v/v) Tween-20, 50 mM Tris-HCl pH 8) by incubation for 7 min at
25 °C. Eluates from TEPSIN-GFP expressing and wild type control cells were then
combined prior to acetone precipitation and analysis by mass spectrometry.
For immunoprecipitation of GFP-RUSC2, wild-type and AP4B1 knockout HeLa
cells stably expressing GFP-RUSC2 (mixed populations), and parental wild-type
HeLa cells, in 100 mm plates were washed once in PBS and then scraped in 500 µL
GFP-trap lysis buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5 mM EDTA,
0.5% NP-40), supplemented with cOmplete™ EDTA-free protease inhibitor (Sigma-
Aldrich). Cells were incubated on ice in lysis buffer for 10 min and then lysates
were cleared by centrifugation at 16,000×g for 10 min. A protein assay was
performed and, if required, lysates were adjusted to equal protein concentrations
with lysis buffer. A portion of each lysate was retained as input and the remainder
was incubated with GFP-Trap A beads at 4 °C for 3 h with rotation. Beads were
washed five times with GFP-trap lysis buffer and then boiled in NuPAGE LDS
Sample Buffer at 75 °C for 10 min to prepare for Western blot analysis.
BioID streptavidin pulldowns. All steps were performed on ice with pre-chilled
ice-cold buffers, unless otherwise noted.
Streptavidin pulldowns for BioID were carried out from HeLa cells stably
expressing BirA*-tagged AP4B1/E1/M1/S1 and control wild-type HeLa, HeLa
BirA* and HeLa GFP-BirA* cells, in triplicate (experiments performed on three
separate days). Cells were cultured in the presence of 50 µM biotin for 24 h prior to
performing the experiment. Cells were harvested by scraping into 5 mL PBS,
pelleted (600×g, 5 min) and washed twice in PBS. Lysis was performed in 1 mL
RIPA buffer (TBS (50 mM Tris-HCl pH 7.4, 150 mM NaCl), 1% NP-40, 0.5%
sodium deoxycholate, 1 mM EDTA, 0.1% SDS) supplemented with cOmplete™
EDTA-free protease inhibitor. DNA was sheared by running the lysates ten times
through a 25 gauge needle, lysates were incubated at 4 °C for 10 min with mixing
and then were sonicated (three times 5 s bursts with an amplitude of 10 µm).
Lysates were cleared by centrifugation (16,000×g, 15 min) and supernatants
transferred to new tubes and normalised to cell pellet weight with RIPA buffer.
Biotinylated proteins were affinity purified using Pierce High Capacity Streptavidin
Agarose (Thermo Fisher Scientific) by incubating with the lysates for 3 h with
rotation at
4 °C. Beads were then pelleted and washed three times in RIPA buffer, twice in TBS
and three times in 50 mM ammonium bicarbonate (ABC) pH 8 (09830, Sigma
Aldrich), before resuspension in 50 mM ABC. Proteins were then reduced by the
addition of 10 mM DTT at 56 °C for 30 min and alkylated by the addition of 55
mM iodoacetamide (I1149, Sigma Aldrich) at room temperature for 20 min in the
dark. Proteins were enzymatically digested by addition of 1 μg Trypsin (V5280,
Promega; stock at 0.1 mg mL−1 in 1 mM HCl) and overnight incubation at 37 °C.
The following day the beads were pelleted, tryptic peptides (supernatant) collected,
spiked with 1 μL 100% trifluoroacetic acid (TFA), dried almost to completion in a
centrifugal vacuum concentrator (Concentrator 5301, Eppendorf) and then stored
at −20 °C. Later samples were thawed, resuspended in a total volume of 100 µL 1%
(v/v) TFA and purified on SDB-RPS StageTips (single shot) as described below.
Preparation of vesicle-enriched fractions. For the comparative proteomic pro-
filing of the vesicle fraction of AP-4-depleted cells, vesicle-enriched fractions were
prepared from paired SILAC-labelled control and AP-4-depleted HeLa cell lines:
wild-type versus AP4B1 knockout (two experiments), wild-type versus AP4E1
knockout (two experiments), wild type (untreated) versus AP-4 knockdown (three
experiments), control (untreated) versus AP-4 knocksideways for 60 min (two
experiments). Replicate experiments were performed on separate days.
All steps were performed on ice with pre-chilled ice-cold buffers, unless
otherwise noted. For each sample eight confluent 15 cm dishes of cells were washed
with PBS and scraped in a total volume of 7.5mL Buffer A (0.1 M MES, pH 6.5,
0.2 mM EGTA and 0.5mM MgCl2). Cells were homogenised with 20 strokes of a
motorised Potter-Elvehjem homogeniser (or a hand-held Dounce homogenizer with
tight pestle) and cell debris was removed by centrifugation at 4150×g for 32min.
Supernatants were treated with 50 μg mL−1 ribonuclease A (MP Biomedicals) for
1 h and then partially digested ribosomes were pelleted by centrifugation (4150×g
for 3 min) and discarded. Membranes were pelleted by centrifugation at 55,000 rpm
(209,900×g RCFmax) for 40min in an MLA-80 rotor (Beckman Coulter).
Membrane pellets were resuspended in 400 μL Buffer A using a 1mL Dounce
homogeniser, mixed with an equal volume of FS buffer (12.5% [w/v] Ficoll and
12.5% [w/v] sucrose, in buffer A) and centrifuged at 20,000 rpm (21,700×g
RCFmax) for 34min in a TLA-110 rotor, to pellet contaminants. Supernatants were
diluted with four volumes of Buffer A and centrifuged at 40,000 rpm (86,700×g
RCFmax) in a TLA-110 rotor for 30 min to obtain the vesicle-enriched fraction
(pellet). Pellets were resuspended in 50 μL 2.5% SDS (in 50mM Tris pH 8), heated
at 65 °C for 3 min and centrifuged to pellet insoluble material (16,000×g, 1 min). For
mass spectrometry, equal amounts of protein (20–50 μg) from paired SILAC-
labelled control and AP-4-depleted vesicle fractions were mixed and either
processed by in-solution or in-gel tryptic digest as described below.
Generation of Dynamic Organellar Maps and membrane fractions. Organellar
maps were prepared from wild-type (control), AP4B1 knockout and AP4E1
knockout HeLa cells, in duplicate (six maps in total). Maps were prepared on two
separate days, with a complete set of three on each occasion (one control, one
AP4B1 knockout, and one AP4E1 knockout).
All steps were performed on ice with pre-chilled ice-cold buffers. HeLa cells
(1 × 15 cm dish SILAC light and 1 × 15 cm dish SILAC heavy per map) were
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washed in PBS (without CaCl2 and MgCl2), incubated in PBS for 5 min, washed in
hypotonic lysis buffer (25 mM Tris-HCl pH7.5, 50 mM sucrose, 0.5 mM MgCl2,
0.2 mM EGTA), and then incubated in hypotonic lysis buffer for 5 min. Cells were
scraped in 4 mL hypotonic lysis buffer and mechanically lysed with 15 strokes of a
Dounce homogeniser (8530700, tight pestle; Sartorius). The sucrose concentration
was then restored to 250 mM. Lysates were centrifuged at 1000×g for 10 min to
pellet nuclear material and post-nuclear supernatants were transferred to new
tubes. The SILAC light post-nuclear supernatant was subfractionated into five
fractions by a series of differential centrifugation steps: 3000×g for 10 min, 5400×g
for 15 min, 12,200×g for 20 min, 24,000×g for 20 min, 78,400×g for 30 min (all
speeds RCF max). All pellets were resuspended in 2.5% SDS/50 mM Tris pH 8 and
heated for 5 min at 72˚C. In parallel, a single membrane fraction was obtained from
the SILAC heavy post-nuclear supernatant by centrifugation at 78,400×g (RCF
max) for 30 min. This fraction served as an internal reference, by spiking it into
each of the “light” subfractions. Analysis by mass spectrometry provided a ratio of
enrichment/depletion for each protein in each subfraction, relative to the standard.
All five ratios combined yielded an abundance distribution profile for each protein
across the subfractions. Principal component analysis revealed which proteins had
similar fractionation profiles (apparent as organellar clusters in Fig. 1g–i). A
detailed description of the method was previously published19.
The membrane fractions analysed by label free quantification (data displayed in
Fig. 2d) are the same as the heavy reference membrane fractions generated during
the preparation of the Organellar maps, but with an additional biological replicate
to give three biological replicates for each cell line.
In-solution digestion of proteins. Protein was precipitated by the addition of 5
volumes of ice-cold acetone, incubated at −20 °C for 30 min and pelleted by
centrifugation at 4 °C for 5 min at 10,000×g. Precipitated protein was rinsed in ice-
cold 80% acetone and re-pelleted as above. All subsequent steps were performed at
room temperature. Precipitated protein pellets were air-dried for 5 min, resus-
pended in digestion buffer (50 mM Tris pH 8.1, 8 M Urea, 1 mM DTT) and
incubated for 15 min. Protein was alkylated by addition of 5 mM iodoacetamide for
20 min and then enzymatically digested by addition of LysC (V1071, Promega; 1
mg per 50 mg of protein) for at least 3 h. Digests were then diluted four-fold with
50 mM Tris pH 8.1 before addition of Trypsin (1 mg per 50 mg of protein) for an
overnight incubation. The peptide mixtures were then acidified to 1% (v/v) TFA in
preparation for peptide purification and fractionation.
Peptide purification and fractionation. Several different peptide fractionation
and clean-up strategies were used in this study. For most mass spectrometric
experiments, peptides were purified and fractionated on SDB-RPS (#66886-U,
Sigma) StageTips69. Peptide mixtures in 1% TFA were loaded onto activated
StageTips and washed with Proteomics Wash Buffer (Preomics) and then 0.2% (v/
v) TFA. For single shot analysis, peptides were eluted with 60 µL Buffer X (80% (v/
v) acetonitrile, 5% (v/v) ammonium hydroxide). For triple-fractionation, peptides
were eluted successively using 20 µL SDB-RPSx1 (100 mM ammonium formate,
40% (v/v) acetonitrile, 0.5% (v/v) formic acid), then 20 µL SDB-RPSx2 (150 mM
ammonium formate, 60% (v/v) acetonitrile, 0.5% formic acid), then 30 µL Buffer X.
For six-fold fractionation, peptides were processed by strong cation exchange
(SCX) on StageTips69. A detailed description of these methods has been pub-
lished69. Alternatively, protein samples were separated by SDS-PAGE, gels were cut
into 5–10 slices, and proteins were digested with trypsin in-gel. Peptide extracts
were then cleaned up on C18-StageTips, before elution in Buffer B (80% (v/v)
acetonitrile, 0.5% (v/v) acetic acid)70. Cleaned peptides were dried almost to
completion in a centrifugal vacuum concentrator, and then volumes were adjusted
to 10 µL with Buffer A* (0.1% (v/v) TFA, 2% (v/v) acetonitrile) and either
immediately analysed by mass spectrometry, or first stored at −20 °C.
The following techniques were applied for the various mass spectrometric
analyses of this study: single shot SDB-RPS: BioID samples and sensitive IPs; triple-
fractionation SDB-RPS: organellar maps analyses, membrane proteome analysis,
vesicle prep analyses (AP-4 knockouts); six-fraction SCX: whole cell lysate full
proteome analysis; in-gel digestion with multiple gel slice fractions: vesicle prep
analyses (AP-4 knockdown, AP-4 knocksideways), conventional IPs.
Mass spectrometry. An overview of the mass spectrometric analyses performed
during this study is provided in Supplementary Table 1. This includes information
on quantification strategy, number of replicates, sample fractionation approach,
MS instrument, and number of MS runs, for each analysis. Two different mass
spectrometers were used (Q-Exactive HF19,20 and Q-Exactive71; Thermo Fisher
Scientific), as indicated in Supplementary Table 1.
Processing of mass spectrometry data. Mass spectrometry raw files were pro-
cessed in MaxQuant72 version 1.5, using the human SwissProt canonical and
isoform protein database, retrieved from UniProt (www.uniprot.org). For SILAC
experiments (vesicle fractions; Dynamic Organellar Map subfractions; whole cell
lysate analysis; TEPSIN-GFP immunoprecipitations) multiplicity was set to 2, with
Lys8 and Arg10 selected as heavy labels; Re-quantify was enabled; minimum
number of quantification events was set to 1. For label-free experiments (mem-
brane fractions; BioID) multiplicity was set to 1; LFQ was enabled, with LFQ
minimum ratio count set to 1. Membrane fractions were SILAC heavy labelled
(Arg10, Lys8). Matching between runs was enabled. Default parameters were used
for all other settings.
Proteomic data analysis. All analyses were performed on the ‘protein groups’ file
output from MaxQuant. Data transformation, filtering and statistical analyses were
performed in Perseus software73 version 1.5 and Microsoft Excel. Principal com-
ponent analysis (PCA) was performed in SIMCA 14 (Umetrics/MKS). PCA plots
(Figs. 1g–i and 2b) show projections along 1st and 3rd principal components, for
optimum visualisation. For all experiments identifications were first filtered by
removing matches to the reverse database, matches based on modified peptides
only, and common contaminants (‘standard filtering’). Further experiment-specific
filtering, data transformation and analyses were performed as described below.
Dynamic Organellar Maps statistical analysis. To identify proteins with shifted
subcellular localisation in response to AP-4 knockout, we applied the rigorous
statistical approach developed in our laboratory19,20. We adapted the procedure to
the experimental design of the present study as follows. Organellar maps were
made in duplicate, from control, AP4B1 knockout and AP4E1 knockout cells.
Abundance distribution profiles across all six maps were determined for 3926
proteins. First, the profiles obtained in the AP4B1 knockout and AP4E1 knockout
cells were subtracted from the profiles obtained in the cognate control map, protein
by protein, to obtain 2 × 2 sets of delta profiles (Con_1-AP4B1_1, Con_2-
AP4B1_2; Con_1-AP4E1_1, Con_2-AP4E1_2). For proteins that do not shift, the
delta profile should be close to zero. All delta profile sets were subjected to a robust
multivariate outlier test, implemented in Perseus software73, to identify proteins
with delta profiles significantly different from experimental scatter. The profile
distance corresponds to a p-value reflecting how likely it is to observe this deviation
by chance, assuming no real change. For each protein, four such p-values were
hence obtained, two from AP4E1 knockout, and two from AP4B1 knockout. For
maximum stringency, we selected the least significant of these p-values as repre-
sentative of a protein’s shift. A shift of equal or greater significance was thus
observed in all four comparisons. We did not treat the four delta maps as com-
pletely independent though, since both knockouts were compared to the same
cognate control. Hence, as a very conservative measure of movement, the selected
p-value was only squared (instead of being raised to the power of four), and then
corrected for multiple hypothesis testing using the Benjamini Hochberg Method.
The negative log10 of the corrected p-value corresponded to a protein’s movement
(M) score.
Next, the reproducibility of observed delta profiles across replicates was
determined as the Pearson correlation (Δmap (Con_1-AP4B1_1) vs. Δmap
(Con_2-AP4B1_2); and Δmap (Con_1-AP4E1_1) vs. Δmap (Con_2-AP4E1_2)).
For maximum stringency, we chose the lower one of the two obtained correlations
as representative of the protein’s shift reproducibility, corresponding to its R score.
To control the false discovery rate (FDR), we then applied the same analysis to
our previously published wild-type HeLa maps19 (six untreated maps with no
genuine protein shifts expected). In this mock experiment, we designated two maps
as controls, two as ‘mock knockout 1’, and two as ‘mock knockout 2′. As above, we
calculated M and R scores from the lowest correlations and p values of movement.
The estimated FDR at a given set of M and R score cut offs was then calculated as
the number of hits obtained with the mock experiment data, divided by the number
of hits obtained with the AP-4 maps data, scaled by the relative sizes of the datasets
(which were almost identical). At the chosen high stringency cut-offs (M-score > 4,
R-score > 0.81), not a single hit was obtained from the mock data. Hence, we
estimate the FDR for the three hits obtained from the AP-4 maps at <1%.
Finally, as an additional criterion, we also evaluated the similarity of identified
shifts across the two different knockouts (i.e. the correlation of Δmap (Con_1-
AP4B1_1) vs Δmap (Con_1-AP4E1_1); and Δmap (Con_2-AP4B1_2) vs Δmap
(Con_2-AP4E1_2)). All three hits showed a very high degree of shift correlation
(>0.9) across the two AP-4 knockout lines, thus also passing the additional
stringency filter.
Membrane fraction analysis. Relative protein levels in membrane fractions from
AP4B1 knockout and AP4E1 knockout HeLa cells (each in biological triplicate)
were compared to those in membrane fractions from wild-type HeLa cells (in
biological triplicate) using LFQ intensity data. The primary output was a list of
identified proteins, and for each protein up to nine LFQ intensities across the wild-
type and AP-4 knockout samples. Following standard data filtering, proteins were
filtered to only leave those with nine LFQ intensities (no missing values allowed),
leaving 6653 proteins. LFQ intensities were then log-transformed and comparison
of knockout and wild-type membrane fractions performed with a two-tailed t-test.
A permutation-based (1000 permutations) estimated FDR of 0.05 and an S0
parameter of 0.5 were set to define significance cut-offs (Perseus software).
Whole cell lysate analysis. Whole cell lysates from light-labelled AP4B1 knockout
and AP4E1 knockout HeLa cells were compared to lysates from heavy-labelled
wild-type HeLa cells by SILAC quantification, each in biological triplicate. The
primary output was a list of identified proteins, and for each protein up to six H/L
(Heavy/Light) ratios of relative abundance (three comparing AP4B1 knockout to
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wild-type and three comparing AP4E1 knockout to wild-type). Following standard
data filtering, proteins were further filtered to require at least two H/L ratios for
each knockout, leaving 6841 proteins. H/L ratios from each replicate were then
normalised to the median H/L ratio for that replicate, log-transformed, and
inverted to L/H so that a protein depleted from the whole cell lysate in the absence
of AP-4 had a negative ratio. A one-sample t-test (two-tailed) was applied to
compare the L/H ratios for each protein to zero (null hypothesis of no change
between wild-type and knockout). To control the false discovery rate (FDR), an
identical analysis of a mock experiment comparing light-labelled and heavy-
labelled wild-type HeLa lysates was performed (in triplicate; no genuine changes
were expected here). The FDR was given by the number of hits observed in the
mock experiment divided by the number of hits in the knockout experiment. Using
the cut-offs p ≤ 0.02 and a minimum absolute fold change (log2) of 0.45, the
estimated FDR was 25%. The t scores from the mock experiment were calculated
from only three datapoints per protein (whereas up to six were used for the
knockout vs control data), and hence were adjusted to emulate a six datapoints
experiment. To this end, we assumed that the observed standard deviations and
means had been observed from six datapoints, yielding much lower p values from
the same t scores for the mock data. This procedure thus likely overestimates the
number of false positives at a given cut-off, resulting in highly stringent FDR
control.
Vesicle fraction analysis. Paired AP-4-depleted and control vesicle fractions were
compared by SILAC quantification. The primary output was a list of identified
proteins, and for each protein up to nine H/L ratios of relative abundance, and the
number of quantification events (H/L ratio count) used to calculate each ratio.
Following standard data filtering, proteins were further filtered to require at least
one H/L ratio count in all experiments. This excluded AP4S1 due to it having a
ratio count of 0 in one experiment, so the data for AP4S1 was manually added back
to the dataset (with one missing datapoint), giving a total of 2848 proteins
quantified across all experiments. H/L ratios from each experiment were then
normalised to the median H/L ratio for that experiment. For experiments in which
the control cells were light labelled, normalised H/L ratios were inverted to L/H,
and then all ratios were log transformed for plotting, so that depletion from the
vesicle fraction in the absence of AP-4 was represented by a positive value. To
identify proteins which were consistently lost from the vesicle fraction from AP-4
depleted cells, the normalised log-transformed SILAC ratios from all nine
experiments were scaled to unit variance and combined by PCA.
TEPSIN-GFP immunoprecipitations. TEPSIN-GFP immunoprecipitations (con-
ventional and sensitive) were compared to control immunoprecipitations by SILAC
quantification. The primary output for each was a list of identified proteins, and for
each protein one or more (up to three) H/L ratios of relative abundance between
the TEPSIN-GFP and control immunoprecipitations, and the number of quanti-
fication events (H/L ratio count) used to calculate each ratio. Following standard
data filtering, unlabelled proteins were filtered out based on having an H/L ratio
< 0.2 in label-swapped replicates. Proteins were further filtered on a minimum H/L
ratio count of 1 in all replicates, leaving 585 proteins for the conventional IP and
1128 proteins for the sensitive IP. H/L ratios from each replicate were normalised
to the median H/L ratio for that replicate. For replicates in which the control cells
were heavy labelled, normalised H/L ratios were inverted to L/H, and then all ratios
were log transformed for plotting, so that enrichment in the TEPSIN-GFP
immunoprecipitation was represented by positive values. The log SILAC ratios
from two replicates were plotted against each other to reveal proteins enriched in
the TEPSIN-GFP immunoprecipitations.
AP-4 BioID. Relative protein levels were compared across samples using LFQ
intensity data. LFQ intensities from pulldowns from the control cell lines (HeLa,
HeLa BirA* and HeLa GFP-BirA*) were compressed from nine values (three cell
lines in triplicate) to three using control compression74. This creates a “worst-case
scenario” control dataset where the three highest LFQ intensities are taken for each
protein. Pulldowns from each AP-4 BioID cell line (in triplicate) were then com-
pared to the compressed control dataset. Proteins were first filtered on LFQ
intensities for valid values in all three replicate pulldowns from the AP-4 BioID cell
line, leaving between approximately 3100–3700 proteins depending on the subunit.
LFQ intensities were then log-transformed, and missing data points were imputed
from a normal distribution with a downshift of 2.2 and a width of 0.3 standard
deviations. Comparisons between control and AP-4 BioID cell lines were per-
formed with a two-tailed t-test. A permutation-based (250 permutations) estimated
FDR of 0.05 and an S0 parameter of 0.5 were set to define significance cut-offs
(Perseus software).
Data availability
The mass spectrometry proteomics data associated with Figs. 1 and 2 have been
deposited to the ProteomeXchange Consortium [http://proteomecentral.
proteomexchange.org] via the PRIDE partner repository75 with the dataset identifier
PXD010103. All other data supporting this work are available on reasonable request to
the corresponding authors.
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